Specific Removal of In Vivo Antibody by Extracorporeal Circulation over an Immunoadsorbent in Gel

ISAAC SCHENKEIN, JEAN-CLAUDE BYSTRYN, and JONATHAN W. UHR

From Irvington House Institute and the Department of Medicine, New York University Medical Center, New York 10016

ABSTRACT A method is described for preparation of a solid immunoadsorbent suspended in an agar gel. The immunoadsorbent in gel retains its specificity. Rabbits were injected with antibody or antigen, and an extracorporeal circulation was established through columns or funnels coated with such immunoadsorbents. It was shown that either antibody or antigen can be specifically and rapidly removed, and that no measurable amounts of antigen from the immunoadsorbent were released into the animals.

INTRODUCTION

Immunoadsorbents have been used to isolate and to purify antibody (see references 1, 2) and to remove specifically reactive cells from heterogeneous populations of lymphocytes (3, 4). We have recently described the use of a solid-phase immunoadsorbent for the removal of antibody from the sera of immunized animals (5, 6). Portions of plasma were exposed to batches of immunoadsorbent, and the adsorbed plasma was returned together with red cells to the animals. By sequential repetition of this procedure, 50–80% of the intravascular antibody could be removed specifically from actively immunized animals. This maneuver is too complicated for general use, however, and also has the disadvantage that trace amounts of immunoadsorbent are released into the animals.

The present study describes the characterization of a solid-phase immunoadsorbent in agar gel and its use in an extracorporeal circulation to remove antibody from immunized animals. With this technique, approximately 80% of $^{131}$I-labeled antibody to bovine serum albumin (BSA) was specifically removed within 30–60 min from passively immunized rabbits. No detectable antigen was released into the animals from the immunoadsorbent.

METHODS

Antigens. Bovine serum albumin 5X crystallized (BSA) was purchased from Pentex Biochemical (Kankakee, Ill.), and Keyhole limpet hemocyanin (KLH) was obtained from Pacific Bio-Marine Supply (Venice, Calif.) and further purified by ultracentrifugation at 100,000 g for 1 hr. Human IgM was obtained from Immunology Inc. (Glenn Ellyn, Ill.). Quantities of proteins in solutions used were estimated spectrophotometrically from the optical densities at 280 and 260 μm, respectively (7).

Antibodies. IgG fractions were purified from sera of rabbits hyperimmunized against BSA, mouse, or chicken IgG, and also from normal rabbits. IgG was salted out with ammonium sulfate, and the dialyzed precipitate was chromatographed on DEAE-cellulose or DEAE-Sephadex (A-25).

Iodination of proteins. Proteins were iodinated with $^{131}$I or $^{125}$I (New England Nuclear Corp., Boston, Mass.) by the method described by McConahey and Dixon (8). The radioactive iodine was NaI which was free of carrier and thiosulfate.

Preparation of solid immunoadsorbent. Bromoacetyl cellulose (BAC) was obtained from Miles-Yeda, Ltd. (Rehovoth, Israel). BAC-protein immunoadsorbents were prepared by the method of Robbins, Haimovich, and Sela (1). The last step of the procedure, i.e. exposure of the adsorbent to 8 M urea was eliminated, since it proved possible to remove all noncovalently bound protein from the cellulose derivative by extensive washing with saline.

Preparation of solid immunoadsorbent agar gel. BAC-BSA or BAC-rabbit IgG was suspended in an equal volume of saline and diluted (1:1 or 1:3) with thorough mixing in melted noble agar (3% in saline) at 50–55°C. The mixture was then poured onto the surface of a glass funnel to form a film or into a mold to form a column. The funnel had been previously coated by a thin film of 1% agar, which was allowed to dry completely. The mold to form the column consisted of a glass tube, 25 cm in length and 0.9 cm in internal diameter into which a glass rod of lesser diameter (0.5 cm) was centered by the use of rubber stoppers. In this manner, an annulus of space was created into which the liquid immunoadsorbent-agar mixture was poured. After hardening of the agar, the glass rod was removed, creating

Dr. Bystryn is the recipient of U. S. Public Health Service Fellowship Dermatology Training Grant T1-AM-5326.

Received for publication 5 February 1971 and in revised form 24 March 1971.

1 Abbreviations used in this paper: BAC, bromoacetyl cellulose; BSA, bovine serum albumin; KLH, Keyhole limpet hemocyanin; PBS, phosphate-buffered saline.
a column lined with immunoadsorbent through which solutions or an animal's blood could be passed.

**Passive immunization.** Albino rabbits weighing 2.5-3 kg were used. About 150 μg of rabbit IgG anti-BSA-\(^{131}\)I or 100-200 μg BSA-\(^{131}\)I was mixed with 4 ml of rabbit antisera to bacteriophage T\(_{2}\) or \(\phi X\) with a titer of neutralizing antibody of 20-50 \(k\) (\(k\) = velocity constant of phage neutralization), and injected into the ear vein. In preliminary experiments using radioiodinated purified IgG of similar anti-T\(_{2}\) activity, it was determined that in antigen excess, T\(_{2}\) binds 1-3 μg of antibody protein per k. On this basis, the quantity of neutralizing antibody to phage, anti-BSA and BSA administered were approximately similar.

**Extracorporeal circulation.** This procedure was performed 4-7 days after passive immunization. Rabbits were premedicated by intravenous injections of atropine (2 mg) and heparin (1000 U/kg). They were anesthetized 30 min later by a slow intravenous injection of sodium pentobarbital (30 mg/kg). The femoral vein and artery were cannulated with a 16 gauge medium intracath (R. C. Bard, Murray Hill, N. J.). Arterial blood was pumped through narrow gauge Teflon tubing by a peristaltic pump (Imico Co., Stoneham, Mass.) and passed through the column or over the funnel lined with immunoadsorbent. The funnel was rotated slowly. Blood was returned to the femoral vein by gravity via a hemoset (Fenwall Laboratories, Inc., Morton Grove, Ill.) fitted with a fine mesh stainless steel filter and supported 100 cm above the animal. Before extracorporeal circulation, the system was primed with 30 ml of fresh normal rabbit blood. The resultant dilution of antibody was corrected for in all subsequent calculations assuming a blood volume of 70 ml/kg rabbit.

**Antibody assays.** Anti-\(\phi X\) or anti-T\(_{2}\) was measured by the phage neutralization technique of Adams (9). The proportion of antibody to BSA in the rabbit anti-BSA-\(^{131}\)I IgG was estimated by the following method. 0.1-ml portions of serum were incubated with 1 ml of the BAC-BSA suspension (containing 37 mg of BSA) at 37°C for 10 min followed by the removal of BAC-BSA by centrifugation (10,000 g, 10 min). This absorption was performed three times using 1 ml of fresh BAC-BSA suspension. The third portion of adsorbent remained virtually free of radioactivity. The total amount of radioactive material removed (corrected for nonspecific adsorption) was used as a measure of antibody specific to BSA.

**Determination of radioactivity.** Radioactive fractions were counted in a Nuclear-Chicago well counter. All counts are net and statistically significant. Spillover of \(^{131}\)I into \(^{125}\)I counts was washed five times each with 3 ml of phosphate-buffered saline (PBS). The agar was then crushed and washed twice with 3 ml of PBS. The last wash was free of radioactivity. The adsorbent was then counted and the percentage of initial radioactivity remaining bound to the immunoadsorbent was calculated.

As can be seen in Table I, 50% of the radioactivity in the purified IgG fraction of an anti-BSA antiserum remained bound to the immunoadsorbent, whereas only 4.7-6% of similarly prepared IgG fractions of antiserum directed against other antigens was bound.

**Differences in binding between radioactive and non-radioactive antibody.** It was necessary to determine whether radioiodination of anti-BSA influenced its binding by the immunoadsorbent. 1 ml of mixtures of radioactive protein and increasing quantities of nonradioactive protein was added to tubes each containing 1 ml of the agar BAC-BSA. After incubation for 15 min at room temperature, the agar immunoadsorbent was washed and prepared for counting as before.

Fig. 1 shows the relationship between bound radio-

### Table I

<table>
<thead>
<tr>
<th>Antigen</th>
<th>Initial counts per minute</th>
<th>Bound to Immunoadsorbent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-BSA</td>
<td>1.8 (\times) 10^4</td>
<td>50</td>
</tr>
<tr>
<td>Anti-mouse IgG</td>
<td>8.1 (\times) 10^4</td>
<td>6.5</td>
</tr>
<tr>
<td>Anti-chicken IgG</td>
<td>2.1 (\times) 10^4</td>
<td>5.6</td>
</tr>
<tr>
<td>Normal</td>
<td>1.9 (\times) 10^4</td>
<td>4.7</td>
</tr>
</tbody>
</table>

*100 μg protein in 1 ml buffer.

---

**RESULTS**

**Specificity of binding of BSA-immunoadsorbent in agar.** To investigate this question, the following experiment was performed: 1 ml of the immunoadsorbent agar suspension was added to plastic test tubes and allowed to solidify. To each tube was added 1 ml of equimolar concentrations (100 μg) of one of the following purified \(^{131}\)I-labeled IgG's: rabbit anti-BSA, rabbit anti-chicken, rabbit anti-mouse, or normal rabbit IgG. After incubation for 15 min at room temperature, the tubes were decanted. The immunoadsorbent agar gel

---

\[^{125}\]I: \(2.7 \times 10^6\) cpm.

\[^{131}\]I: \(6.7 \times 10^6 - 1.3 \times 10^7\) cpm.

---

**Removal of In Vivo Antibody** 1865

---

**Figure 1** Competition for binding sites on BAC-BSA by anti-BSA-\(^{131}\)I and unlabeled anti-BSA. Increasing amounts of unlabeled anti-BSA were added to a fixed amount of anti-BSA-\(^{131}\)I (0.1 μg), and the binding of radioactivity to immunoadsorbent was measured. The insert shows a plot of the same data as a logarithmic relationship.
TABLE II
Removal of In Vivo Anti-BSA by Extracorporeal Circulation over BSA-BAC in Agar Gel

<table>
<thead>
<tr>
<th>Animal no.</th>
<th>Pre-operative Anti-BSA-131I</th>
<th>Post-operativeAnti-BSA-131I</th>
<th>Removed</th>
<th>Pre-operative Anti-phage</th>
<th>Post-operative Anti-phage</th>
<th>Removed</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>cpm/0.1 ml</td>
<td>%</td>
<td></td>
<td>cpm</td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>519</td>
<td>86</td>
<td>83</td>
<td>0.13</td>
<td>0.12</td>
<td>8</td>
</tr>
<tr>
<td>2</td>
<td>347</td>
<td>58</td>
<td>83</td>
<td>0.07</td>
<td>0.06</td>
<td>14</td>
</tr>
<tr>
<td>3</td>
<td>306</td>
<td>57</td>
<td>81</td>
<td>0.21</td>
<td>0.19</td>
<td>10</td>
</tr>
<tr>
<td>4</td>
<td>752</td>
<td>154</td>
<td>79</td>
<td>0.10</td>
<td>0.09</td>
<td>10</td>
</tr>
</tbody>
</table>

* Counts per minute, which can be removed from serum after adsorption with BAC-BSA, corrected for nonspecific binding of protein to immunoadsorbent.

† Value has been corrected for dilution by "priming" blood volume.

activity and proportion of unlabeled anti-BSA. The insert shows logarithmic plot of these data. The effect of increasing amounts of unlabeled anti-BSA on the binding behavior of radioactive anti-BSA indicates competition of unlabeled and radioactive protein for binding sites on the solid immunoadsorbent.

In vivo removal of antibody by extracorporeal circulation. The ability of the immunoadsorbent lined columns or funnels to remove antibody from the circulation of animals was determined. Four rabbits were passively immunized with anti-BSA-131I and either anti-φX or anti-Tx. 4–7 days later, the animals were anesthetized, and their blood was circulated through an immunoadsorbent-lined funnel or column. The extracorporeal circulation was maintained for 30–60 min. Levels of antibody to BSA and bacteriophage were determined on portions of serum obtained from bleedings at the beginning and the end of the procedure.

As can be seen in Table II, 79–83% of circulating anti-BSA was removed in the four animals tested. In contrast, the levels of circulating antibody to bacteriophage were only decreased by 8–14%. The amount of antibody removed ranged from 17 to 61 μg of protein as calculated from the specific radioactivity of the anti-BSA and the total radioactivity removed. It is not known whether all the antigenic sites on the immunoadsorbent were saturated with antibody.

Release of antigen from BSA-immunoadsorbent in agar. In order to determine whether BSA bound to the BAC-agar was released and entered the circulation during the procedure, the BSA in the immunoadsorbent used in the previous experiments had been labeled with 131I. Three of the above experimental rabbits were sacrificed at the end of the extracorporeal circulation. The entire thyroid, spleen, kidneys, 10% of liver weight, several grams of muscle tissue, 5 ml of blood, and in one case both lungs were collected, and the level of radioactivity due to 131I was determined.

As can be seen in Table III, no significant 131I counts could be found in the organs tested though 1 × 107 cpm 131I-labeled BSA was present on the immunoadsorbent used.

TABLE III
Release of BSA from Immunoadsorbent

<table>
<thead>
<tr>
<th>Animal no.</th>
<th>Amount of BSA-131I in Immunoadsorbent</th>
<th>Amount of BSA-exposed in tissues of treated rabbits</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>cpm</td>
<td>Blood†</td>
</tr>
<tr>
<td></td>
<td>cpm in whole organ</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>1 × 10⁸</td>
<td>63</td>
</tr>
<tr>
<td>3</td>
<td>1 × 10⁸</td>
<td>63</td>
</tr>
<tr>
<td>4</td>
<td>1 × 10⁸</td>
<td>66</td>
</tr>
</tbody>
</table>

* Counting background of the well counter.
† 5.0 ml.
‡ 10% of total liver weight.
∥ 5 g.

1866 I. Schenken, J.-C. Bystryn, and J. W. Uhr
Experiments with antibody-containing immunoadsorbent in agar. Analogous experiments to those described above for the BSA-immunoadsorbent were performed with anti-BSA immunoadsorbent.

(a) Specificity of binding was demonstrated. In an in vitro experiment in which equimolar amounts of proteins-125I were used (1.6–2.9 × 10⁶ cpm), 52% of BSA was bound in contrast with 43% of rabbit gamma globulin and 6.9% of KLH.

(b) No difference in the binding of 125I and unlabeled BSA was detected. 100–2500 μg of BSA was added to a fixed amount of BSA-125I (1 × 10⁶ cpm) in an experiment entirely analogous to that described earlier for rabbit anti-BSA. A logarithmic plot of radioactivity bound versus increasing amounts of unlabeled BSA resulted in a straight line.

(c) Specific removal of BSA-125I in vivo was demonstrated. Two rabbits were injected intravenously with 100 μg of unlabeled BSA and 6.7 × 10⁶ cpm of BSA-125I as well as rabbit anti-BSA. 5 days later extracorporeal circulation was performed using BAC-anti-BSA in agar gel. 24–27% of the circulating BSA-125I was removed, whereas the level of the control protein was decreased by 10–15%. The smaller proportion of specific removal compared with the earlier experiments may be due to an immunoadsorbent agar ratio of 1:3 in contrast with the 1:1 ratio used in the experiments involving removal of anti-BSA. It is also possible that removal using antibody-containing immunoadsorbent will be less efficient since removal depends on the correct orientation of the antibody molecule on the surface of the gel.

DISCUSSION

Methods for removing antibody in vivo have been described in the past, but they have limited potential for general clinical use. Thus, both plasmapheresis (10–12) and exchange transfusion (13) remove antibody nonspecifically and, in addition, carry the risk of serum hepatitis.

The present studies indicate that antibody can be removed specifically and rapidly from the circulation of immunized animals. The technique used was to incorporate an immunoadsorbent (e.g. BAC-BSA) into agar, thus forming a solid gel which was used to line the inside of glass columns and funnels. After extracorporeal circulation through such columns or over such funnels, approximately 80% of intravascular antibody was removed in 30–60 min. In contrast, the levels of a control antibody remained virtually unchanged throughout the procedure. No detectable antigen was released from the immunoadsorbent into the animals used in these experiments. The actual amounts injected and removed were small. However, there exists a proportionality between surface area of the immunoadsorbent in gel and its capacity to remove specific materials. We therefore suggest that with appropriate development in engineering, the capacity for specific removal could be easily and strikingly increased.

The possibility of manipulating humoral antibody levels by this simple and effective method has several experimental and therapeutic implications. Experimentally, it should be possible to probe further into the physiological mechanisms regulating the synthesis of antibody. Therapeutically, this method could be applied to remove autoantibodies involved in the pathogenesis of disease or to remove the "blocking" antibody believed to play a role in the propagation of tumors (14–17). An unresolved problem in therapeutic application is that the removal of antibody in actively immunized animals is followed by a rapid rise of serum antibody back to the original levels (6, 18). A possible solution applicable to autoimmune diseases would be the subsequent administration of specific antibody which cannot bind C' such as Fab' or F(ab')₂, but which can suppress antibody synthesis (19, 20).

We have also shown that antibody conjugated to the solid immunoadsorbent in gel can be used to remove antigen from the circulation. Hence, using the specificity of antibody, it should be possible to remove any circulating molecule, provided an antibody can be prepared to it. Using the appropriate immunoadsorbent, components of complement, hormones, endotoxin, digitalis, or toxic chemicals could be removed. Moreover, different immunoadsorbents could be used in sequence. For example, simultaneous use of antibody and antigen-containing immunoadsorbents would allow removal of immune reactants from patients with immune complex disease without the necessity of establishing whether the patient is in the phase of antigen or antibody excess.

ACKNOWLEDGMENTS

We are grateful to Mrs. Lai Yook Lim for excellent technical assistance.

This work was done under the sponsorship of the Commission on Immunization of the Armed Forces Epidemiological Board and was supported in part by the U. S. Army Medical Research Development Command, Department of the Army, under research contract DADA 17-69-C-9177, in part by U. S. Public Health Service Grants AI-0834 and HE-09239, and by the National Science Foundation Grant GB-7473-X.

REFERENCES


Removal of In Vivo Antibody 1867